Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206076 · ClinicalTrials.gov registry record · Phase 4
Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
A Phase 4 study, sponsored by Albert Einstein Healthcare Network.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT00206076 is a Phase 4 study that has completed, run by Albert Einstein Healthcare Network. The registered enrollment target is 19 participants.
The verdict
NCT00206076, a Phase 4 study, has completed, sponsored by Albert Einstein Healthcare Network.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to reduce the potential side effects from using cyclosporine or tacrolimus.
Interventions
- DRUG mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206076
The ClinicalTrials.gov registry entry for NCT00206076 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein Healthcare Network, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mycophenolate mofetil is the first listed.
NCT00206076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206076 about?
NCT00206076 is a clinical study titled "Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation". The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to reduce the potential side effects from using cyclosporine or tacrolimus.
What is the current status of trial NCT00206076?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2006-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00206076?
The interventions under investigation include: mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT00206076?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.